Pulmokine Inc Information

Pulmokine is a privately held biopharmaceutical company. The mission of Pulmokine is to develop new treatments for pulmonary hypertension and related disorders. Pulmokine has an exclusive license from Gilead to develop a portfolio of PDGFR inhibitors for PAH. Funding sources include equity investment and NIH grants. Pulmokine pursues in-licensing and partnership opportunities related to pulmonary and cardiovascular diseases. We also provide fee for service work for pre-clinical efficacy studies. Our capabilities include measurement of pulmonary function, telemetry pressure monitoring, measurement of pressure volume loops, and drug delivery by inhalation. In addition Pulmokine is developing a novel class of kinase inhibitors through in silico modeling and in vitro screening to treat asthma and idiopathic pulmonary fibrosis.